The revised bid consists of 0.4013 Curaleaf shares and 1.00 dollar in cash for each Aurora share. This represents an 86 percent premium over Aurora’s unaffected share price of 2.75 dollars, recorded before the initial offer was launched in August. If the cash holdings on Aurora’s balance sheet are excluded, the premium climbs to 217 percent. Curaleaf also introduced a cap price of 6.00 dollars per share to further incentivize the deal.

While filing the updated paperwork with Canadian and U.S. regulators, Curaleaf leadership dismissed technical objections raised by Aurora, specifically regarding pro forma financial statements. The company maintains that these issues are distractions rather than valid regulatory roadblocks. By voluntarily addressing these points, Curaleaf aims to clear the path for a comprehensive evaluation of the combined business potential. Shareholders can now access the updated tender offer documentation through the SEC and SEDAR+ systems, as the firm continues to apply pressure for a formal response from the Aurora board.